Global Spine Biologics Market is valued approximately at USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than 4% over the forecast period 2021-2027. Spine biologics promote bone growth creation during the inflammatory, healing, and remodeling stages of spine fusion surgery for the treatment of spinal abnormalities such as trauma, tumors, degenerative disc disease, and spinal cord injuries. As a consequence, the popularity of biologics has been fueled by an increase in the number of spinal fusion surgeries. The market is driven by Growing Prevalence of Spine Deformities and Growing Geriatric Population. According to the American Association of Neurological Surgeons, 17,000 new cases of spinal cord injury are recorded in the United States each year. As a result, the number of cases of spinal cord injuries will increase leading to the need for treatment of disorders. Furthermore, a number of companies are developing and providing natural bone grafts harvested from the donor body. Zimmer Biomet, for example, offers RegenerOss Resorbable Xenograft (natural bone grafts). The presence of products from such well-known and worldwide firms indicates that there is a market for spinal bone grafts. However, reimbursement policies, may impede market growth over the forecast period of 2021-2027.

The global market for spine biologics is dominated by North America, followed by Europe. Stable economic growth, growing acceptance of minimally invasive procedures, and rising incidence of spine disorders such as spinal stenosis, disc-related problems, and spondylolisthesis are all factors contributing to the market’s growth. Because of the vast patient pool and rising knowledge of biologics’ advantages among surgeons and patients, the Asia Pacific market is expected to develop significantly. Improvements in the region’s infrastructure and healthcare facilities, growing healthcare costs, and a high frequency of spine injuries are all factors drive the market growth.

Major market player included in this report are:
Stryker Corporation
Johnson And Johnson
Medtronic plc
Exactech, Inc
Orthofix Medical Inc.
Arthrex, Inc.
Spine Wave, Inc.
Zimmer Biomet
K2M Inc.
DePuy Synthes

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Spinal Allografts
Bone Graft Substitutes
By End user:
Ambulatory Surgical Centers
By Region:
North America

Asia Pacific
South Korea
Latin America
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027.

Target Audience of the Global Spine Biologics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers